Skip to main content

Table 5 Proportion of symptomatic TEs in patients receiving a platinum-based regimens (cisplatin or carboplatin) in combination with gemcitabine, docetaxel or vinca alkaloids

From: Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study

 

% (events/pts)

(95% CI)

Platinum-based regimen*

Nadroparin

Placebo

Relative risk

Without gemcitabine

1.5 (3/201)

4.5 (4/89)

0.33 (0.08-1.45)

With gemcitabine

2.2 (2/90)

10.2 (5/49)

0.22 (0.04-1.08)

Without docetaxel

2.2 (5/224)

6.5 (7/108)

0.34 (0.11-1.06)

With docetaxel

0.0 (0/67)

6.7 (2/30)

N.D.

Without vinca alkaloids

1.6 (4/252)

6.3 (8/127)

0.25 (0.08-0.82)

With vinca alkaloids

2.6 (1/39)

9.1 (1/11)

0.28 (0.02-4.15)

  1. *Platinum-based regimen: cisplatin or carboplatin
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us